GLOBULIN TEST, HUMAN THYROXINE BINDING— 510(k) K781225

Name: FDA 510(k) clearance K781225
Creator: U.S. Food and Drug Administration
Published: 1978-08-31

Substantially Equivalent

Hyland Therapeutic Div., Travenol Laboratories

FDA 510(k) clearance K781225 for GLOBULIN TEST, HUMAN THYROXINE BINDING, Substantially Equivalent on 1978-08-31. Applicant: Hyland Therapeutic Div., Travenol Laboratories. Device class: 2.

Clearance details

Applicant: Hyland Therapeutic Div., Travenol Laboratories
Product code: Code CEE
Device class: Class 2
Regulation: 21 CFR 862.1685
Advisory panel: Clinical Chemistry
Date received: 1978-07-18
Decision date: 1978-08-31
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Mchenry, IL, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code CEE

view all

K952284 — AMERLITE TBG ASSAY1995-07-26
K930010 — ACCESS THYROID UPTAKE ASSAY1993-06-07
K910677 — IMMULITE(TM) T-UPTAKE1991-04-29
K905777 — MICROZYME THYROID UPTAKE ENZYME IMMUNOASSAY KIT1991-01-30
K900240 — DELFIA TBG KIT1990-03-30

More clearances from Hyland Therapeutic Div., Travenol Laboratories

view all

K820835 — ALUMINA SILICA-ACTIVATED PARTIAL THROM1982-04-26
K820192 — HAEMOPHILUS INFLUENZAE TYPE B ANTISERUM1982-03-11
K812220 — NEPHELOMETRIC SOLID TURBIDITY STANDARD1981-08-18
K810078 — Q-PAK THERAPEUTIC DRUG MONIT. CONTROL S1981-02-02
K810077 — OMEGA THERAPEUTIC DRUG MONIT. CONTROL S.1981-01-28

Data sourced from openFDA. This site is unofficial and independent of the FDA.